About EverLife Capital
EverLife helps business owners, investors and successful professionals understand which longevity biotech companies may deserve closer attention before the field becomes mainstream.
I am Eric Pemper. I spent more than 25 years building and leading companies. I am not a doctor, scientist, registered investment adviser, broker-dealer, or fiduciary. I am an operator and independent research publisher studying the intersection of aging biology, company building, capital allocation, and healthy human lifespan.
An exciting story is not a decision process. EverLife evaluates each company through two lenses: whether its technology could contribute to longer, healthier lives and whether the company could create financial value at the valuation and terms available. The 25-Gate Framework keeps the science, human evidence, leadership, financing, valuation, access and risk visible.
The Thesis
Breakthrough technologies don’t become obvious overnight. Artificial intelligence, the internet, electric vehicles, and robotics all went through long periods where commercial returns felt theoretical.
Longevity biotech looks similar:
Early capability exists, but the path to meaningful impact and investment clarity isn’t yet consensus.
EverLife Capital exists to study that inflection point with disciplined thinking, not to predict the future, but to build a research framework before the field becomes crowded or obvious.
The 4‑Minute Mile Effect
Before Roger Bannister broke the four‑minute mile, many believed it couldn’t be done. Once it happened, the boundary shifted, and others followed. Longevity biotech may still be early. Most companies will fail. Some science won’t translate. Timelines may take longer than expected. That is why a structured framework matters.
Who I Am
I'm Eric Pemper, founder of CuraDebt and independent longevity biotech publisher.
I am not a doctor, scientist, registered investment adviser, or fiduciary. I am an operator and research publisher who studies the intersection of business, science, capital allocation, and healthspan potential.
My background includes:
B.S. in computer engineering from the University of California in San Diego
25+ years building and leading companies
Creating repeatable frameworks for evaluating hard problems
Applying that discipline to study longevity biotech
How EverLife Evaluates Companies
EverLife Capital uses a structured 25‑Gate Framework to evaluate longevity biotech companies across:
Scientific rationale & mechanism quality
Clinical development path
Leadership and capital discipline
Regulatory timeline
Commercial potential
Financial risk
Companies are organized into a Research Tracker, Research Scout list and Watchlist. These are research classifications, not buy lists, ratings or recommendations. Each classification includes the evidence, valuation questions and next milestone that could change the assessment.
What You’ll Get
EverLife Capital publishes research notes including:
Company research and write‑ups
Mechanism deep dives
Framework updates and evolution
25-Gate scores, valuations and milestone updates
Watchlist/observable signals
Commentary on areas such as inflammation, cellular reprogramming, senescence, cardiovascular biology, and other healthspan‑related fields
When I have a financial interest in a company discussed, I disclose it clearly. I currently hold positions in Yuva Biosciences and Repair Biotechnologies.
What This Is Not
EverLife Capital is not:
Investment advice
Medical advice
A managed investment fund
Personalized financial planning
I do not know your financial situation, risk tolerance, time horizon, or medical circumstances. Nothing published here is tailored to you or should be construed as a recommendation to buy, sell, or hold any security. Consult qualified professionals for financial, legal, and medical decisions.
Important Disclosures
EverLife Capital is an independent research publication intended for general educational purposes only. It is not registered with the SEC as an investment adviser. Content should be viewed as impersonal commentary and research, not individualized advice.
FAQ
Is EverLife Capital investment advice?
No. EverLife Capital is educational research and impersonal commentary only. It is not investment, legal, tax, medical, or personalized financial advice. Nothing published here is a recommendation to buy, sell, hold, allocate to, or avoid any security, company, fund, or private investment.
Are you a registered investment adviser?
No. I am not a registered investment adviser, broker-dealer, physician, scientist, fiduciary, or fund manager. I publish independent educational research based on my own study of longevity biotech companies, mechanisms, clinical developments, and market activity.
What does EverLife Capital publish?
The core publication is a weekly deep dive on a longevity biotech company, mechanism, clinical development, or industry pattern that I believe is worth understanding. Most issues focus on one of three areas:
Mechanisms of aging
The top causes of death and major age-related diseases
Earlier-stage breakthrough science that could matter if the biology translates
When something important happens in the industry - such as a major acquisition, partnership, clinical readout, regulatory development, or “smart money” move by pharma or institutional investors - I may publish an additional note.
What is the research tracker?
The research tracker is a hypothetical, paper-only tool I use to test my 25-Gate Framework over time. It is not a real-money portfolio, not a fund, not a managed account, and not a product offered to subscribers. When a company is added to the tracker, it means the framework flagged it as worth continued observation. It does not mean I am recommending the company or that I believe anyone should buy it.
What is the watchlist?
The watchlist is for companies, mechanisms, or scientific areas that are interesting but not yet strong enough for the research tracker. A company may be placed on the watchlist because the science is promising but early, the clinical data is incomplete, the capital structure is unclear, the company overlaps too closely with another tracked company, or the risk/reward picture is not yet developed enough.
How do you decide which company is the “best pick” for a deep dive?
Each deep dive uses my 25-Gate Framework to compare companies across science, clinical evidence, leadership, capital discipline, competitive positioning, commercial potential, and risk.
Sometimes the “best pick” is not the highest-quality company in isolation. It may be the company that adds the most differentiated exposure to a mechanism, avoids duplicating an existing tracker company, or offers the clearest way to study a biological theme.
The framework does not pick stocks. It helps me decide what is worth studying more closely.
Do you personally invest in companies you write about?
Sometimes. When I have a financial interest in a company discussed, I disclose it clearly. I currently hold personal equity in Repair Biotechnologies and Yuva Biosciences. My personal holdings are not recommendations. They may be illiquid, high-risk, private, early-stage, or unsuitable for other people. Readers should not rely on my personal activity as guidance for their own decisions.
Who is EverLife Capital for?
EverLife Capital is written for business owners, professionals, investors, family offices, and lifelong learners who want to understand longevity biotech with more clarity and less hype.
The goal is to help readers understand what may matter in the future of healthy aging, not to tell anyone what to buy.
How can I contact the publisher?
Please email: [email protected].
About EverLife Capital
EverLife helps people outside the biotechnology industry discover longevity biotech companies that may deserve closer attention before the field becomes mainstream.
I’m Eric Pemper. I spent more than 25 years building companies and sold most of my businesses in 2026. Along the way, I evaluated company pitches, invested my own money, made mistakes and lost money. Those experiences led me to build a repeatable 25-gate framework for studying longevity biotechnology more carefully.
Each week, I explain what a company is building, what has actually been demonstrated, what the company may be worth, the principal risks and the evidence that matters next. I continue to evaluate companies for my own research and possible future investment.
Before EverLife, I founded CuraDebt.
Discover the Companies